BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16451200)

  • 1. Inhibitory effects on HLA-DR1-specific T-cell activation by influenza virus haemagglutinin-derived peptides.
    Li X; Li R; Li Z
    Tissue Antigens; 2006 Jan; 67(1):45-52. PubMed ID: 16451200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The inhibitory effect of hyporesponsive peptide on human leukocyte antigen-DRbeta1 specific T cell activation].
    Zhou Q; Cheng YJ; Li ZG; Zhou WH; Lu HS
    Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1505-9. PubMed ID: 14521731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virus haemagglutinin-derived peptides inhibit T-cell activation induced by HLA-DR4/1 specific peptides in rheumatoid arthritis.
    Li X; Li R; Li Z
    Clin Exp Rheumatol; 2006; 24(2):148-54. PubMed ID: 16762149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The study of inhibitory peptides on T cell activation in rheumatoid arthritis].
    Li X; Li R; Zhang CH; Li ZG
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(24):1679-82. PubMed ID: 16251070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibitory effect of altered collagen II peptide on HLA-DRB1-restricted T-cell activation.
    Cheng YJ; Zhou Q; Li ZG
    Scand J Immunol; 2005 Mar; 61(3):260-5. PubMed ID: 15787743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between HLA-DR4/1 subtypes and T cell response to influenza virus hemagglutinin or anti-HA308-317 antibodies in rheumatoid arthritis].
    Li X; Li R; Li ZG
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1881-3. PubMed ID: 19039998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of T-cell activation with HLA-DR1/DR4 restricted Non-T-cell stimulating peptides.
    Zhou Q; Cheng Y; Lü H; Zhou W; Li Z
    Hum Immunol; 2003 Sep; 64(9):857-65. PubMed ID: 12941540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered collagen II peptides inhibited T-cell activation in rheumatoid arthritis.
    Li R; Li X; Li Z
    Clin Immunol; 2006; 118(2-3):317-23. PubMed ID: 16343992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered peptide ligands of islet autoantigen Imogen 38 inhibit antigen specific T cell reactivity in human type-1 diabetes.
    Geluk A; van Meijgaarden KE; Roep BO; Ottenhoff TH
    J Autoimmun; 1998 Aug; 11(4):353-61. PubMed ID: 9776713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen.
    Rosloniec EF; Whittington KB; Zaller DM; Kang AH
    J Immunol; 2002 Jan; 168(1):253-9. PubMed ID: 11751969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effect of polymorphism at HLA-DR1 beta-chain positions 85 and 86 on binding and recognition of DR1-restricted antigenic peptides.
    Newton-Nash DK; Eckels DD
    J Immunol; 1993 Mar; 150(5):1813-21. PubMed ID: 7679697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of antigen-specific T cell activation by staphylococcal enterotoxins.
    Dowd JE; Jenkins RN; Karp DR
    J Immunol; 1995 Feb; 154(3):1024-31. PubMed ID: 7822779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior molecularly altered influenza virus hemagglutinin peptide 308-317 inhibits collagen-induced arthritis by inducing CD4+ Treg cell expansion.
    Sun J; Li R; Guo J; Jia Y; Sun X; Liu Y; Li Y; Huang F; Lu L; Li Z
    Arthritis Rheum; 2012 Jul; 64(7):2158-68. PubMed ID: 22231228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of HLA-DR residues at positions 67, 71, and 86 in interaction between HLA-DR11 and peptide HA306-320.
    Zeliszewski D; Golvano JJ; Gaudebout P; Dorval I; Freidel C; Gebuhrer L; Betuel H; Borras-Cuesta F; Sterkers G
    J Immunol; 1993 Dec; 151(11):6237-47. PubMed ID: 7504016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of natural polymorphism at residue 86 of the HLA-DR beta chain on peptide binding.
    Busch R; Hill CM; Hayball JD; Lamb JR; Rothbard JB
    J Immunol; 1991 Aug; 147(4):1292-8. PubMed ID: 1869824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allopeptide-specific T cell reactivity altered by peptide analogs.
    Colovai AI; Liu Z; Harris PE; Cortesini R; Suciu-Foca N
    J Immunol; 1997 Jan; 158(1):48-54. PubMed ID: 8977174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of autoimmune arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen.
    Rosloniec EF; Brand DD; Myers LK; Esaki Y; Whittington KB; Zaller DM; Woods A; Stuart JM; Kang AH
    J Immunol; 1998 Mar; 160(6):2573-8. PubMed ID: 9510154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen presentation of mycobacterial peptides to human T cell clones can be immunomodulated by adding an MHC-specific inhibitor.
    Méndez-Samperio P
    Cell Immunol; 1993 Apr; 148(1):1-9. PubMed ID: 8495481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides.
    Ishioka GY; Adorini L; Guery JC; Gaeta FC; LaFond R; Alexander J; Powell MF; Sette A; Grey HM
    J Immunol; 1994 May; 152(9):4310-9. PubMed ID: 8157954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of monoclonal antibodies to a synthetic peptide of influenza haemagglutinin on the processing and presentation of viral antigens to class II-restricted T-cell clones.
    Mills KH
    Immunology; 1988 Nov; 65(3):365-71. PubMed ID: 2463222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.